Table 1 summarizes evidence from preclinical studies showing that inhibiting NLRP3 may reduce cytokines and other proinflammatory protein production, suggesting a novel therapeutic target for IBS via regulation of inflammation. Here, NLRP3 is linked to irritable bowel syndrome.